Zivo Bioscience Files 8-K: Officer Departures & Compensation
Ticker: ZIVO · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001101026
| Field | Detail |
|---|---|
| Company | Zivo Bioscience, Inc. (ZIVO) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-departure, compensation, regulation-fd
TL;DR
Zivo Bioscience leadership changes and compensation details out in new 8-K.
AI Summary
Zivo Bioscience, Inc. filed an 8-K on March 30, 2026, reporting on the departure of certain officers and directors, and compensatory arrangements. The filing also includes Regulation FD disclosures and financial statements/exhibits, with a press release and a CEO letter to shareholders attached as exhibits.
Why It Matters
This filing provides crucial updates on the company's leadership and executive compensation, which can significantly impact investor confidence and future strategic direction.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation can signal internal shifts or financial pressures that may affect the company's stability and future performance.
Key Numbers
- 15 — Documents (Number of documents filed with the 8-K)
Key Players & Entities
- Zivo Bioscience, Inc. (company) — Filer of the 8-K report
- 0001101026 (company) — CIK number for Zivo Bioscience, Inc.
- 2026-03-30 (date) — Filing date of the 8-K
- 2026-03-26 (date) — Period of report for the 8-K
FAQ
What specific officer or director positions were affected by the departures mentioned in Item 5.02?
The filing indicates departures of 'Directors or Certain Officers' and 'Appointment of Certain Officers' but does not specify names or exact positions within the provided summary text.
What are the details of the compensatory arrangements for certain officers mentioned in Item 5.02?
The filing mentions 'Compensatory Arrangements of Certain Officers' as part of Item 5.02, but specific details are not provided in the summary text and would require reviewing the attached exhibits.
What is the primary content of the press release (EX-99.1) attached to this 8-K filing?
The press release is listed as an exhibit (EX-99.1) and is likely to contain the key information being disclosed by Zivo Bioscience, Inc. under Regulation FD.
What is the purpose of the CEO Letter to Shareholders (EX-99.2) included in the filing?
The CEO Letter to Shareholders (EX-99.2) is an exhibit intended to communicate directly with the company's investors, likely providing context or further details on the matters reported in the 8-K.
What is the significance of the XBRL filings included with this 8-K?
The XBRL (eXtensible Business Reporting Language) filings provide structured, machine-readable financial data, allowing for easier analysis and comparison of Zivo Bioscience's financial information.
Filing Stats: 774 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2026-03-30 08:01:49
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to p
Filing Documents
- zivo_8k.htm (8-K) — 28KB
- zivo_ex991.htm (EX-99.1) — 8KB
- zivo_ex992.htm (EX-99.2) — 15KB
- 0001654954-26-002928.txt ( ) — 186KB
- zivo-20260326.xsd (EX-101.SCH) — 5KB
- zivo-20260326_lab.xml (EX-101.LAB) — 15KB
- zivo-20260326_cal.xml (EX-101.CAL) — 1KB
- zivo-20260326_pre.xml (EX-101.PRE) — 11KB
- zivo-20260326_def.xml (EX-101.DEF) — 5KB
- zivo_8k_htm.xml (XML) — 5KB
01 Other Events
Item 7.01 Other Events. On March 27, 2026, the Company issued a press release announcing its intention to file a Form 15 with the Securities and Exchange Commission to suspend the Company's reporting obligations on March 30, 2026, under Section 13 and 15(d) of the Securities and Exchange Act of 1934, as amended, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On March 27, 2026, the Company's Chief Executive Officer issued a letter to the shareholders, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 7.01, and Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless we expressly set forth in such filing that such information is to be considered "filed" or incorporated by reference therein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 27, 2026 99.2 CEO Letter to Shareholders, dated March 27, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZIVO BIOSCIENCE, INC. By: /s/ John Payne John Payne Chief Executive Officer Date: March 27, 2026 3